Journal of International Reproductive Health/Family Planning ›› 2023, Vol. 42 ›› Issue (6): 492-497.doi: 10.12280/gjszjk.20230216

• Review • Previous Articles     Next Articles

Clinical Studies of MSCs and MSCs-Derived Exosomes in Premature Ovarian Insufficiency, and Research Progress

XIANG Chun-rong, DENG Zhi-min, DAI Fang-fang, CHENG Yan-xiang()   

  1. Department of Obstetrics and Gynecology, Renmin Hospital of Wuhan University, Wuhan 430060, China
  • Received:2023-05-26 Published:2023-11-15 Online:2023-11-09
  • Contact: CHENG Yan-xiang E-mail:yanxiangCheng@whu.edu.cn

Abstract:

Premature ovarian insufficiency (POI) is one of the common causes of infertility in women of reproductive age, which has a serious impact on women′s physiological and psychological health. The incidence of POI is increasing year by year, and the etiology and mechanism of POI are diverse and complex. The existing therapeutic methods in clinic are limited. Hormone replacement therapy, the most commonly used method, focuses on improving patients′ symptoms and fails to fundamentally restore the ovarian function. With the development of regenerative medicine, the transplantation of mesenchymal stem cells (MSCs) and MSCs-derived exosomes (MSCs-EXOs) has been found to be able to repair the ovarian function and improve the fertility of POI patients by promoting granulosa cells (GCs) proliferation, inhibiting GCs apoptosis, anti-inflammation, anti-oxidation, anti-fibrosis, and by promoting angiogenesis and follicle development, as well as regulating immunity and other mechanisms, which brings new prospects for POI treatment. However, its safety and effectiveness still need to be further studied and verified.

Key words: Premature ovarian insufficiency, Mesenchymal stem cells, Exosomes, Granulosa cells, Ovarian reserve